Under the newly approved rules, UC senior executives who want to sit on corporate boards, consult for companies or engage in other external corporate activities must first make the case for how UC would benefit from their work. The revised conflict-of-interest regulations only apply to executives who are seeking outside corporate work from now on. Currently, about 50 out of 165 UC senior executives hold such positions and are exempt from the new rules, according to the report.
Twelve executives are working with for-profit companies, including UCSF Medical Center CEO Mark Laret, whose pay recently came under scrutiny. Mr. Laret has received payments totaling more than $5 million in stock awards and cash since 2007 for his role on the boards of two companies that do millions of dollars of business with the hospital: Palo Alto, Calif.-based Varian Medical Systems and Burlington, Mass.-based Nuance Communications.
During the meeting Thursday, the regents also approved 3 percent raises for the top UC executives, one day after several UC employees staged a protest over wages they said are so low that many have had to cut back on spending on food and move out of city apartments, according to the report.
More articles on compensation:
4 surprising trends in resident pay, training
2015 physician compensation, work RVU by specialty
Board director pay up to $263,500
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
